Investigational Drug Information for Plitidepsin
✉ Email this page to a colleague
What is the drug development status for Plitidepsin?
Plitidepsin is an investigational drug.
There have been 16 clinical trials for Plitidepsin.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2010.
The most common disease conditions in clinical trials are COVID-19, Neoplasms, Plasma Cell, and Multiple Myeloma. The leading clinical trial sponsors are PharmaMar, Apices Soluciones S.L., and Ministry of Health, France.
Summary for Plitidepsin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,518 |
| WIPO Patent Applications | 1,039 |
| Japanese Patent Applications | 516 |
| Clinical Trial Progress | Phase 3 (2010-06-01) |
| Vendors | 22 |
Recent Clinical Trials for Plitidepsin
| Title | Sponsor | Phase |
|---|---|---|
| Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care | PharmaMar | Phase 2 |
| Extension Study in a Cohort of Adult Patients With COVID-19 Infection | Apices Soluciones S.L. | Phase 1/Phase 2 |
| Extension Study in a Cohort of Adult Patients With COVID-19 Infection | PharmaMar | Phase 1/Phase 2 |
Clinical Trial Summary for Plitidepsin
Top disease conditions for Plitidepsin
Top clinical trial sponsors for Plitidepsin
US Patents for Plitidepsin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
